Randomized Study in Children and Adolescents With Migraine: Acute Treatment
for Pediatric Migraine
Sites in Washington D.C. +77 more locations
Sponsor: Pfizer
Sex: All·Age: 6 - 17
Code: NCT04649242·Phase 3·Recruiting·Listed Dec 2020
Clinical Trials at Children's National Medical Center
As of August 2026, 84 paid clinical trials are recruiting at Children's National Medical Center in Washington D.C., District of Columbia. Active studies at this site cover conditions such as Breast Cancer, Sickle Cell Disease and Stroke. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Filter results
84 clinical trials at Children's National Medical Center
·Clear filters· Get a weekly email when new trials open in Washington D.C., DC.
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
for Acute Treatment of Migraine
Drug: Rimegepant
Sites in Washington D.C. +60 more locations
Sponsor: Pfizer
Sex: All·Age: 6 - 17
Code: NCT04743141·Phase 3·Recruiting·Listed Feb 2021
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
for Type 2 Diabetes
Drug: Dulaglutide
Sites in Washington D.C. +40 more locations
Sponsor: Eli Lilly and Company
Sex: All·Age: 10 - 17
Code: NCT06739122·Phase 3·Recruiting·Listed Dec 2024
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
for Neoplasms
Sites in Washington D.C. +24 more locations
Sponsor: Eli Lilly and Company
Sex: All·Age: 1 - 39
Code: NCT05999994·Phase 2·Recruiting·Listed Aug 2023
Child and Adolescent Registry for Participants With Narcolepsy
for Narcolepsy
Sites in Washington D.C. +24 more locations
Sponsor: Jazz Pharmaceuticals
Sex: All·Age: Up to 17
Code: NCT04899947·Recruiting·Listed May 2021
A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
for Noonan Syndrome
Drug: Vosoritide
Sites in Washington D.C. +19 more locations
Sponsor: BioMarin Pharmaceutical
Sex: All·Age: 3 - 11
Code: NCT06668805·Phase 2·Recruiting·Listed Oct 2024
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
for Heart Failure
Sites in Washington D.C. +19 more locations
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 29 Days - 17
Code: NCT05714085·Phase 2, Phase 3·Recruiting·Listed Feb 2023
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
for Autosomal Recessive Polycystic Kidney (ARPKD)
Sites in Washington D.C. +5 more locations
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Sex: All·Age: 28 Days - 18
Code: NCT04782258·Phase 3·Recruiting·Listed Mar 2021
Study of Olutasidenib and Temozolomide in HGG
for High Grade Glioma
Sites in Washington D.C. +10 more locations
Sponsor: Rigel Pharmaceuticals
Sex: All·Age: 12 - 39
Code: NCT06161974·Phase 2·Recruiting·Listed Dec 2023
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
for Pulmonary Arterial Hypertension
Sites in Washington D.C. +8 more locations
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 1 - 17
Code: NCT05587712·Phase 2·Recruiting·Listed Oct 2022
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
for Hypochondroplasia
Drug: Vosoritide
Sites in Washington D.C. +9 more locations
Sponsor: BioMarin Pharmaceutical
Sex: All·Age: 0 Months - 36 Months
Code: NCT07126262·Phase 2·Recruiting·Listed Aug 2025
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
for Dravet Syndrome
Sites in Washington D.C. +21 more locations
Sponsor: Longboard Pharmaceuticals
Sex: All·Age: 2 - 65
Code: NCT06660394·Phase 3·Recruiting·Listed Oct 2024
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
for Low-grade Glioma
Sites in Washington D.C. +11 more locations
Sponsor: Day One Biopharmaceuticals, Inc.
Sex: All·Age: 6 Months - 25
Code: NCT04775485·Phase 2·Recruiting·Listed Mar 2021
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
for Depressive Disorder, Major
Sites in Washington D.C. +9 more locations
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 12 - 17
Code: NCT07227454·Phase 3·Recruiting·Listed Nov 2025
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
for Heterozygous Familial Hypercholesterolemia (HeFH)
Drug: Enlicitide Decanoate
Sites in Washington D.C. +6 more locations
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 6 - 17
Code: NCT07058077·Phase 2, Phase 3·Recruiting·Listed Jul 2025
A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects
for Benign Centrally-Located Intracranial Tumors
Sites in Washington D.C. +2 more locations
Sponsor: InSightec
Sex: All·Age: 5 - 22
Code: NCT03028246·Recruiting·Listed Jan 2017
Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
for Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Sites in Washington D.C. +3 more locations
Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company
Sex: All·Age: 0 - 17
Code: NCT07080385·Phase 2, Phase 3·Recruiting·Listed Jul 2025
Novel Device for Ultrasound-guided Pediatric Vessel Cannulations
for Clinical Procedures Which Require Vessel Cannulations in Pediatric Patients
1 location in Washington D.C.
Sponsor: Clear Guide Medical
Sex: All·Age: 1 Month - 17
Code: NCT04039490·Recruiting·Listed Jul 2019
Duchenne Electronic Health Record Study
for Duchenne Muscular Dystrophy (DMD)
Sites in Washington D.C. +9 more locations
Sponsor: The Duchenne Registry
Sex: All·Age: All ages
Code: NCT07609394·Recruiting·Listed May 2026
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
for Childhood Extracranial Germ Cell Tumor
Sites in Washington D.C. +381 more locations
Sponsor: Children's Oncology Group
Sex: All·Age: All ages
Code: NCT03067181·Phase 3·Recruiting·Listed Mar 2017
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
for Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Drug: Nivolumab
Sites in Washington D.C. +379 more locations
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 5 - 60
Code: NCT05675410·Phase 3·Recruiting·Listed Jan 2023
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
for Hematopoietic and Lymphatic System Neoplasm
Sites in Washington D.C. +190 more locations
Sponsor: Children's Oncology Group
Sex: Female·Age: Up to 39
Code: NCT06513962·Phase 3·Recruiting·Listed Jul 2024
Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma
for Posterior Fossa Ependymal Tumor
Sites in Washington D.C. +9 more locations
Sponsor: University of California, San Francisco
Sex: All·Age: 1 - 39
Code: NCT07226453·Phase 2·Recruiting·Listed Nov 2025
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
for B Acute Lymphoblastic Leukemia
Sites in Washington D.C. +186 more locations
Sponsor: Children's Oncology Group
Sex: All·Age: 365 Days - 25
Code: NCT03959085·Phase 3·Recruiting·Listed May 2019
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
for B Acute Lymphoblastic Leukemia
Sites in Washington D.C. +137 more locations
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 366 Days - 46
Code: NCT06124157·Phase 2·Recruiting·Listed Nov 2023
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
for Acute Myeloid Leukemia
Sites in Washington D.C. +168 more locations
Sponsor: Children's Oncology Group
Sex: All·Age: Up to 21
Code: NCT04293562·Phase 3·Recruiting·Listed Mar 2020
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
for Acute Leukemia of Ambiguous Lineage
Drug: Venetoclax
Sites in Washington D.C. +111 more locations
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: Up to 365 Days
Code: NCT06317662·Phase 2·Recruiting·Listed Mar 2024
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
for Recurrent Langerhans Cell Histiocytosis
Sites in Washington D.C. +100 more locations
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 180 Days - 22
Code: NCT05828069·Phase 2·Recruiting·Listed Apr 2023
Project: Every Child for Younger Patients With Cancer
for Adrenal Gland Pheochromocytoma
Sites in Washington D.C. +226 more locations
Sponsor: Children's Oncology Group
Sex: All·Age: Up to 25
Code: NCT02402244·Recruiting·Listed Mar 2015
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
for Stage I Mixed Cell Type Kidney Wilms Tumor
Sites in Washington D.C. +152 more locations
Sponsor: Children's Oncology Group
Sex: All·Age: Up to 30
Code: NCT06401330·Phase 3·Recruiting·Listed May 2024
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
for Anaplastic Kidney Wilms Tumor
Sites in Washington D.C. +171 more locations
Sponsor: Children's Oncology Group
Sex: All·Age: Up to 30
Code: NCT04322318·Phase 2·Recruiting·Listed Mar 2020
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
for Malignant Glioma
Drug: Selinexor
Sites in Washington D.C. +105 more locations
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 12 Months - 21
Code: NCT05099003·Phase 1, Phase 2·Recruiting·Listed Oct 2021
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
for Low Grade Astrocytoma
Drug: Selumetinib
Sites in Washington D.C. +116 more locations
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 2 - 21
Code: NCT04166409·Phase 3·Recruiting·Listed Nov 2019
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
for Stage II Nasopharyngeal Carcinoma AJCC v8
Drug: Nivolumab
Sites in Washington D.C. +74 more locations
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: Up to 21
Code: NCT06064097·Phase 2·Recruiting·Listed Oct 2023
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
for Acute Lymphoblastic Leukemia
Sites in Washington D.C. +155 more locations
Sponsor: PedAL BCU, LLC
Sex: All·Age: Up to 22
Code: NCT04726241·Phase 1, Phase 2·Recruiting·Listed Jan 2021
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
for Metastatic Malignant Neoplasm in the Lung
Sites in Washington D.C. +201 more locations
Sponsor: Children's Oncology Group
Sex: All·Age: Up to 50
Code: NCT05235165·Phase 3·Recruiting·Listed Feb 2022
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
for Basal Ganglia Germinoma
Sites in Washington D.C. +94 more locations
Sponsor: Children's Oncology Group
Sex: All·Age: 3 - 29
Code: NCT06368817·Phase 2·Recruiting·Listed Apr 2024
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
for Ganglioneuroblastoma, Nodular
Sites in Washington D.C. +153 more locations
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: Up to 30
Code: NCT06172296·Phase 3·Recruiting·Listed Dec 2023
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
for Ganglioneuroblastoma
Sites in Washington D.C. +142 more locations
Sponsor: Children's Oncology Group
Sex: All·Age: 365 Days - 30
Code: NCT03126916·Phase 3·Recruiting·Listed Apr 2017
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
for Central Nervous System Nongerminomatous Germ Cell Tumor
Sites in Washington D.C. +140 more locations
Sponsor: Children's Oncology Group
Sex: All·Age: 3 - 29
Code: NCT04684368·Phase 2·Recruiting·Listed Dec 2020
Common conditions studied in Washington D.C.
- Breast Cancer (15 active studies)
- Sickle Cell Disease (12 active studies)
- Stroke (11 active studies)
- Heart Failure (9 active studies)
- Obesity (9 active studies)
- Prostate Cancer (9 active studies)
Leading research sponsors in Washington D.C.
- Children's National Research Institute
- Georgetown University
- National Cancer Institute (NCI)
- George Washington University
- Medstar Health Research Institute
Frequently asked questions
How many paid clinical trials are currently recruiting in Washington D.C.?
There are approximately 844 recruiting clinical trials in Washington D.C., District of Columbia listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Washington D.C. pay participants?
Most recruiting trials in Washington D.C. compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Washington D.C.?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Washington D.C.?
The most common conditions under active study in Washington D.C. include Breast Cancer (15), Sickle Cell Disease (12), Stroke (11), Heart Failure (9), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Washington D.C.?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Washington D.C. on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Washington D.C.?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Washington D.C.?
Recruiting research sites in Washington D.C. include MedStar Washington Hospital Center, Children's National Medical Center, Children's National Hospital, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Washington D.C. right now?
The largest active categories in Washington D.C. are Cancer & tumors (293), Neurology & pain (65), Cardiovascular (52). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.